Wedbush Upgrades Cidara Therapeutics (CDTX) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 rises; Apple and Palantir set to report results
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts CDTX Hot Sheet
Price: $221.38 --0%
Rating Summary:
13 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 21 | Down: 25 | New: 16
Rating Summary:
13 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 21 | Down: 25 | New: 16
Join SI Premium – FREE
Wedbush analyst Robert Driscoll upgraded Cidara Therapeutics (NASDAQ: CDTX) from Neutral to Outperform with a price target of $4.00 (from $2.00).
For an analyst ratings summary and ratings history on Cidara Therapeutics click here. For more ratings news on Cidara Therapeutics click here.
Shares of Cidara Therapeutics closed at $2.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Upgrades Lumentum (LITE) to Strong Buy, 'Overreaction to Marvell Offer'
- Freedom Broker Upgrades Nucor (NUE) to Buy
- DA Davidson Upgrades Franklin Electric (FELE) to Buy
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
